MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2022 International Congress

September 15-18, 2022. Madrid, Spain.

View by Title View Categories
Jump to:  View All • a b c d e f g h i j k l m n o p q r s [t] u v w x y z
  • T1 posterior fossa radiomics based diagnosis of Essential tremor

    J. Saini, S. Prasad, A. Rajan, P. Pal, M. Ingalhalikar (Bangalore, India)

  • Targeted training improves touchscreen skills in Parkinson’s disease and healthy elderly

    J. de Vleeschhauwer, E. Nackaerts, B. Vandendoorent, Y. Zhang, L. Janssens, A. Nieuwboer (Leuven, Belgium)

  • Task Specific Oromandibular dystonia due to Shisha (Hookah) Smoking- “Shisha Dystonia”

    S. Mittal, H. Yu, P. Krystkowiak (Abu Dhabi, United Arab Emirates)

  • Task-Specific Dystonia is a predominant disorder of Top-Down Sensorimotor integration

    S. Merchant, M. Hallett (Boston, USA)

  • Telemedicine in a Himalayan country: unlocking the barrier in the management of Parkinson’s Disease

    R. Ojha, B. Gajurel, R. Karn, R. Rajbhandari, G. Nepal, J. Yadav, P. Joshi (Kathmandu, Nepal)

  • Telemedicine in speech and swallowing disorders for patients with Parkinson’s disease: Motivation and satisfaction of patients and speech language pathologists

    Y. Manor, D. Shpunt, A. Zait, A. Ezra, N. Hezi, L. Jokel, H. First, N. Karin, M. Zirler, M. Kalish, L. Raif, A. Migirov Sandrovitz, T. Gurevich1 (Tel Aviv-Yafo, Israel)

  • Telephone nursing care for Parkinson’s patients: one-year experience in a tertiary referral hospital in Italy

    C. Tedesco, M. Campagnolo, M. Carecchio, F. Pistonesi, V. Cianci, M. Garon, R. Biundo, V. Misenti, A. Baba, A. Antonini (Padua, Italy)

  • Temporal Dynamic Alterations of Regional Homogeneity in Parkinson’s disease: A Resting-State fMRI Study

    T. Yuan, L. Kai, S. Wen (Beijing, China)

  • Temporal dynamics and longitudinal predictors of apathy in Parkinson’s disease

    C. Le Heron, M. Macaskill, K. Horne, L. Livingstone, T. Melzer, D. Myall, T. Pitcher, J. Dalrymple-Alford, T. Anderson, S. Harrison (Christchurch, New Zealand)

  • Temporal segmentation of FOG using AFSD algorithm on RGB data and on walkway pressure data

    M-K. Lu, Y-W. Wang, C-H. Tsai, T. Debusschere, K-C. Hsu (Taichung City, Taiwan)

  • Test-Retest Reliability of the PDQ-Carer

    D. Morley, S. Dummett, D. Churchman, L. Kelly, C. Jenkinson (Oxford, United Kingdom)

  • Testamentary Capacity Assessment Tool (TCAT): An update report

    P. Voskou, A. Douzenis, A. Economou, S. Papageorgiou (Athens, Greece)

  • Thalamic white matter macrostructure and subnuclei volumes in Parkinson’s disease depression

    R. Bhome, A. Zarkali, G. Thomas, J. Iglesias, J. Cole, R. Weil (London, United Kingdom)

  • The 20-item Noise Pareidolia Task is uniquely sensitive to Visual Hallucinations in Parkinson’s Disease

    T. Turner, F. Rodriguez-Porcel (Charleston, USA)

  • The acceptability of wearable devices to measure mobility in people with Parkinson’s Disease: observations from Mobilise-D

    A. Keogh, L. Alcock, P. Brown, M. Brozgol, E. Gazit, C. Hansen, J. Hausdorff, W. Maetzler, L. Rochester, A. Yarnall, B. Caulfield (Dublin, Ireland)

  • The Achilles’ heel of a craftsman, a complication of Guillain-Barré Syndrome

    S. Lopes, O. Costa, L. Costa, C. Machado, S. Varanda (Braga, Portugal)

  • The agreement between automated and expert FOG annotations during an at-home protocol: influence of dopaminergic medication and task

    N. D'Cruz, D. Zoetewei, T. Herman, P. Ginis, J. Hausdorff, A. Nieuwboer (Leuven, Belgium)

  • The anti-alpha-synuclein antibody Lu AF82422 binds to pathological alpha-synuclein species from human brains and inhibits seeded alpha-synuclein aggregation

    P. Kallunki, K. Willén, F. Sotty, L. Buur, K. Bjerregaard-Andersen, M. Lubas, D. Damlund, M. Harndahl, K. Fog (Valby, Denmark)

  • The anti-alpha-synuclein antibody Lu AF82422 was safe and well tolerated in a FIH-SAD study in healthy subjects and patients with PD

    L. Buur, J. Wiedemann, F. Larsen, F. Ben Alaya-Fourati, P. Kallunki, D. Ditlevsen, M. Sørensen, D. Meulien (Valby, Denmark)

  • The association of CSF sTREM2 with cognitive decline and its dynamic change in Parkinson’s disease: Analysis of the PPMI Cohort

    Q. Qixiong, W. Hengming, W. Danlei, L. Jingyi, Q. Yi, Z. Jingwei, L. Jiangting (Wu han, China)

  • The barriers and facilitators to satisfaction with botulinum neurotoxin treatment in people with cervical dystonia: a systematic review.

    M. Boyce, A. Mccambridge, L. Bradnam, C. Canning, A. Verhagen (Ultimo, Australia)

  • The benefit of exclusive nocturnal administration of a levodopa-carbidopa intestinal infusion for severe refractory sleep behavior disorder in Parkinson’s disease

    M. Rivera Sánchez, A. Sánchez Rodríguez, M. Sierra, I. González-Aramburu, MV. Sánchez Peláez, M. Martínez, J. Infante (Santander, Spain)

  • The brain-age framework in Parkinson’s disease: evaluating MRI morphometry and sex-dimorphism

    G. Gonzalez-Escamilla, P. Farag, M. Bange, S. Groppa (Mainz, Germany)

  • The burden of non-motor symptoms in adult-onset, focal, idiopathic dystonia: A comparative cross-sectional study

    D. Garg, S. Sharma, A. Srivastava (New Delhi, India)

  • The changes in activities of daily livings after deep brain stimulation in Parkinson’s disease

    T. Yamamoto, M. Suzuki, S. Hirano, Y. Yamanaka, A. Sugiyama, N. Araki, Y. Higuchi, S. Kuwabara (Chiba, Japan)

  • The clinical challenge of an unilateral abnormal uptake in datscan

    C. Silva, F. Barros, F. Matias, CM. Machado, FM. Moreira, M. Cunha, A. Morgadinho (Coimbra, Portugal)

  • The Comparison of Constipation scoring system scales between Parkinson’s disease and non-Parkinson’s disease patients with constipation

    K. Methawasin, A. Krittayasingh, P. Chonmaitree, M. Wongwandee, N. Kongsakorn (Nakhon Nayok, Thailand)

  • The Complexity of Parkinson Disease Medication Regimens May Factor into Treatment Decisions: Results of a PMD Alliance Survey

    J. Farmer, C. Goas, J. Rivera, A. Mitchell, A. Merriam, N. Crouse, A. Formella (Pennington, USA)

  • The Correlation Analyses of Parkinson’s Disease with Serum Homocysteine, Folic Acid and Vitamin B12

    YP. Chen, Y. Qu, JT. Li, Z. Min, YJ. Xiong, Z. Xue (Wuhan, China)

  • The correlation between genetic factors and freezing of gait in patients with Parkinson’s disease

    B. Radojević, N. Dragašević-Mišković, A. Milovanović, M. Svetel, I. Petrović, I. Jančić, D. Stanisavljević, O. Milićević, M. Savić, V. Kostić (Belgrade, Serbia)

  • The cortical thickness signature and future phenoconversion in isolated REM-sleep behavior disorder: a longitudinal analysis

    JH. Shin, JY. Lee, HJ. Kim, YK. Kim, EJ. Yoon, HW. Nam, B. Jeon (Seoul, Republic of Korea)

  • The countless visual features in PD and their impact on quality of life. A standardized diagnostic protocol

    M. Meglio, E. Olivola, E. Palermo, G. Fioretto, D. D'Innocenzo, D. Centonze, N. Modugno (Pozzilli, Italy)

  • The cross-talk between microglia-derived exosomes and brain printing biometrics as a diagnostic approach for Parkinson’s disease prior to motor symptoms implications

    M. Anwar, M. Fathi (Cairo, Egypt)

  • The development of a screening tool to identify movement disorders in patients with inborn errors of metabolism

    L. Koens, M. Klamer, D. Sival, B. Balint, K. Bhatia, M. Contarino, M. van Egmond, R. Erro, J. Friedman, V. Fung, C. Ganos, M. Kurian, A. Lang, E. Mcgovern, E. Roze, T. de Koning, M. Tijssen (Groningen, Netherlands)

  • The distinctive functional connectivity of the cholinergic nucleus basalis of Meynert in Parkinson’s disease across different motor subtypes

    M. Nazmuddin, P. Zeidman, T. van Laar (Surabaya, Indonesia)

  • The East London Parkinson Disease Project – engaging a diverse population in research

    A. Zirra, A. Ben-Joseph, T. Haque, D. Gallagher, C. Budu, B. Huxford, C. Simonet, A. Noyce (London, United Kingdom)

  • The Edmond J. Safra Fellowship in Movement Disorders: A Global Network of Parkinson’s Experts

    R. Dolhun (New York, USA)

  • The Effect of a Boxing Exercise Program on Laryngeal Function in People with Parkinson’s Disease

    Z. Thijs, C. Watts (Fort Worth, USA)

  • The effect of co-administration of opicapone on the pharmacokinetics of levodopa

    D. Kamiyama, N. Nishikawa, G. Oyama, T. Hatano, N. Hattori (Tokyo, Japan)

  • THE EFFECT OF DEEP BRAIN STIMULATION ON LOWER URINARY TRACT SYMPTOMS IN PARKINSON’S DISEASE

    P. Araújo, A. Francisco, R. de Fraga, L. Frizon, M. ávila, I. Filho, L. Pancera, G. Schaidt, J. Goginski, A. Farinazzo (Curitiba, Brazil)

  • The effect of Deep Brain Stimulation on Sense of agency in Parkinson’s disease patients with and without impulsive compulsive behaviours.

    L. Ricciardi, A. de Angelis, MP. Stenner, F. Baig, E. Pereira, S. Di Costa, MJ. Edwards, P. Haggard, F. Morgante (London, United Kingdom)

  • The effect of levodopa on speech in patients with Parkinson’s disease

    M. Mrackova, R. Marecek, J. Mekyska, M. Kostalova, R. Rektorova (Brno, Czech Republic)

  • The Effect of Oropharyngeal Resting Tremor on Swallow Timings in a Clinical Cohort of People with Parkinson’s Disease

    M. Dumican, K. Harper (Kalamazoo, USA)

  • The effect of rasagiline on nocturnal hypokinesia: the analysis of the Nocturnal Hypokinesia Questionnaire (NHQ)

    J. Sringean, R. Bhidayasiri (Bangkok, Thailand)

  • The effect of short-term treadmill exercise in the alpha-synuclein preformed fibril rat model of Parkinson’s disease

    S. Fleming, J. Patterson, C. Kemp, J. Lepp, E. Hamad, S. Scott, J. Holden, A. Davis, C. Szarowicz, J. Lipton, M. Kubik, N. Kuhn, A. Stoll, K. Luk, C. Sortwell (Rootstown, USA)

  • The effect of split-belt-treadmill training on freezing related gait deficits in people with Parkinson’s disease

    C. Schlenstedt, J. Seuthe, F. Hulzinga, N. D'Cruz, P. Ginis, A. Nieuwboer (Hamburg, Germany)

  • The effects of converting to Dysport from other botulinum toxin type A formulations for treating cervical dystonia patients

    O. Samotus, M. Jog (London, Canada)

  • The effects of on-demand auditory cueing on home-based freezing of gait in people with Parkinson’s disease

    D. Zoetewei, T. Herman, L. Palmerini, A. Ferrari, J. Hausdorff, A. Nieuwboer, P. Ginis (Leuven, Belgium)

  • The Efficacy of a Remote Cognitive Remediation Therapy (CRT) Program on Parkinson’s Disease

    N. Piniella, N. Burt, S. Yasin, N. Volino, M. Baker, M. Jung, A. Leder, A. Sousa, L. Hoffman (Glen Head, USA)

  • The efficacy of Botulinum toxin A in reducing muscle spasticity by different volumes of dilution

    R. Marvulli, G. Ianieri, G. Mintrone, A. Zonno, L. Rizzo, G. Farì, M. Ranieri, M. Megna (Bari, Italy)

  • The frequency of glucocerebrosidase mutations in a subgroup of early-onset Parkinson’s disease patients in the Korean population

    J. Lee, J. Hwangbo (Yangsan, Republic of Korea)

  • The functional neuroanatomy of cortical slowing predicts clinical features of Parkinson’s disease

    A. Wiesman, E. Fon, S. Baillet (Montreal, Canada)

  • The Genetic Landscape of Parkinson’s disease in populations of non-Caucasian ancestry.

    C. Koros, AM. Simitsi, N. Papagiannakis, A. Bougea, I. Pachi, R. Antonelou, M. Stamelou, L. Stefanis (Athens, Greece)

  • The Hidden Disease Burden and Treatment Experience of Patients with Essential Tremor: A Retrospective US Claims Analysis

    C. Vetterick, K. Lyons, R. Pendal, G. Belfort, B. Ravina (Boston, USA)

  • The impact of COVID-19 on Parkinson’s disease: a case-controlled registry and questionnaire study

    G. Cedergren Weber, P. Odin, J. Timpka (Lund, Sweden)

  • The impact of Parkinson’s disease on multifactorial aspects of attention

    O. Peleg, Z. Ktzir, I. Maidan, D. Levy, A. Mirelman (Tel Aviv, Israel)

  • The impact of thyroid disease on severity of motor symptoms in Croatian residents with de novo Parkinson’s disease

    I. Sarac, H. Sarac, F. Borovecki, I. Ivek, L. Bagaric Krakan, Z. Kresic, M. Iveta, T. Sukobljevic (Zagreb, Croatia)

  • The influence of GBA and LRRK2 on mood disorders in Parkinson’s Disease

    A. Thaler, N. Omer, B. Cohen, N. Giladi, M. Kestenbaum, J. Shirvan, J. Cedarbaum, M. Gana-Weisz, O. Goldstein, A. Orr-Urtreger, A. Mirelman (Tel-Aviv, Israel)

  • The integration of technology into a home-based visuo-cognitive training intervention for people with Parkinson’s: a theory-informed qualitative study.

    J. Das, G. Barry, R. Walker, R. Vitorio, R. Morris, S. Stuart (Newcastle upon Tyne, United Kingdom)

  • The Journey Of Levodopa Treatment in Parkinson’s disease

    B. Pandey (Tirupati, India)

  • The key is “any movement”: results from a Cochrane systematic review and network meta-analysis on physical interventions for Parkinson´s disease

    M. Ernst, AK. Folkerts, M. Roheger, D. Chakraverty, F. Krohm, J. Caro-Valenzuela, R. Gollan, E. Lieker, A. Adams, C. Eggers, I. Monsef, A. Dresen, N. Skoetz, E. Kalbe (Cologne, Germany)

  • The level of glial neurotrophic factor in blood plasma depending on the stage of Parkinson’s disease

    R. Matmurodov, M. Muminov, A. Abduqodirov, K. Khalimova (Tashkent, Uzbekistan)

  • The Lion’s tail family: A Bavarian multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson’s disease with dementia

    A. Fanciulli, F. Leys, F. Lehner, V. Sidoroff, V. Ruf, C. Raccagni, P. Mahlknecht, D. Kuipers, W. van Ijcken, H. Stockner, T. Musacchio, J. Volkmann, C. Monoranu, I. Stankovic, G. Breedveld, F. Ferraro, C. Fevga, O. Windl, J. Herms, S. Kiechl, W. Poewe, K. Seppi, N. Stefanova, S. Scholz, V. Bonifati, G. Wenning (Innsbruck, Austria)

  • The Magnetic Resonance Parkinsonism Index as a diagnostic marker for differentiating PSP from IPD

    L. Haupt, S. Kannenberg, J. Caspers, C. Hartmann, A. Schnitzler (Düsseldorf, Germany)

  • The mGlu2 positive allosteric modulator BINA extends enhances low dose L-DOPA anti-parkinsonian action in the MPTP-lesioned marmoset

    C. Kwan, I. Frouni, S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

  • The mitochondrial risk score and lifestyle factors are associated with age at onset in LRRK2 p.Gly2019Ser Parkinson’s disease.

    T. Lüth, C. Gabbert, P. Lajer, I. König, A. Caliebe, S. Koch, B-H. Laabs, F. Hentati, S. Sassi, R. Amouri, C. Klein, A. Grünewald, M. Farrer, J. Trinh (Lübeck, Germany)

  • The non-motor features of essential tremor with midline distribution

    A. Rekik, I. Kacem, S. Mrabet, Y. Abida, A. Gharbi, A. Souissi, A. Gargouri, A. Nasri, R. Gouider (Tunis, Tunisia)

  • The noradrenergic basis of Parkinson’s tremor

    A. Heide, M. Wessel, D. Papadopetraki, D. Geurts, T. van Prooije, F. Gommans, R. Helmich (Nijmegen, Netherlands)

  • The overexpression of a-SYN leads to a differential process of mitophagy in neurons and atrocytes

    I. Lastres-Becker, S. Castro-Sánchez, I. Silva-Llanes, P. Teresak, JL. Lanciego, E. Sierra, P. Boya (Madrid, Spain)

  • The Parkinson’s Incidence Cohorts Collaboration (PICC): an international collaboration of incident PD cohorts

    A. Macleod, J. Maple-Grødem, M. Camacho, R. Lawson, D. Bäckström, A. Yarnall, C. Williams-Gray, G. Alves, O. Tysnes, L. Forsgren, C. Counsell (Aberdeen, United Kingdom)

  • The phenomenon of unexpectedly high functional mobility in people with typical Parkinson’s disease. A cross-sectional data analysis.

    A-M. Hanff, C. Mccrum, G. Aguayo, A. Rauschenberger, A. Leist, R. Krüger, M. Zeegers (Strassen, Luxembourg)

  • The position of students of communication sciences and disorders department at Ono Academic College regarding telepractice vs. face-to-face internship experience in speech and swallowing therapy for patients with movement disorders.

    Y. Manor, D. Shpunt, A. Zait, O. Abramov, D. Biteulin Maharat, A. Avraham, A. Twik-Klein, I. Feldman, T. Gurevich, H. Putter Katz (Tel Aviv-Yafo, Israel)

  • The potential role of Per- and Polyfluoroalkyl Substances (PFAS) in movement disorders: Implications and Risk assessment to Human Health

    N. Verma (Barotiwala, India)

  • The prevalence of helicobacter pylori in Parkinson’s disease

    N. Mansurova (Tashkent, Uzbekistan)

  • The profile of dysautonomia in the early stages of Parkinson’s disease and multiple system atrophy: the importance of using the SCOPA-AUT scale

    M. Jecmenica-Lukic, I. Stankovic, A. Tomic, N. Kresojevic, V. Markovic, I. Petrovic, N. Dragasevic, M. Svetel, V. Kostic (Belgrade, Serbia)

  • The reasons for referral to a Parkinson’s Clinical Psychology service

    R. Lewis-Morton, B. Mohamed, E. Thomas, S. Mahon, T. Williams (Cardiff, United Kingdom)

  • The relationship between cognitive function, fear of falling, and history of fall in people with Parkinson’s disease

    H. Khalil, A. Al-Sharman, R. Rehan, N. Alissa, A. Aburub, K. El-Salem (Doha, Qatar)

  • The relationship between sleep and Parkinson’s disease progression: A Mendelian Randomization study

    E. Matar, M. Mahjoub (Sydney, Australia)

  • The relationship of non-motor symptoms in Parkinson’s disease

    E. Golchenko, Y. Karakulova (Perm, Russian Federation)

  • The reliability and validity of the Ziegler test for measuring freezing of gait in people with Parkinson’s disease.

    L. Goh, S. Paul, C. Canning, K. Ehgoetz Martens, J. Song, S. Campoy, N. Allen (Camperdown, Australia)

  • The REONPARK (REgistry of the use of COMT-inhibitors in the maNagement of patients with PARKinson’s disease in Spain who present early motor fluctuations) study: rationale and design of a national, multicentre and prospective study

    L. Lopez-Manzanares, E. Casas-Peña, I. Muro-Garcia, I. Caballero, F. Almeida, I. Tegel, P. Sarasa (Madrid, Spain)

  • The results of DBS in patients with Parkinson’s disease for 10 years in Belarus

    A. Buniak, V. Alexeyevets, S. Likhachev (Minsk, Belarus)

  • The role of cortical and subcortical structures in maintaining efficient network topology in Parkinson’s disease

    R. Berlot, B. Koritnik, Z. Pirtošek (Ljubljana, Slovenia)

  • The role of GBA1 mutations in the relationship between GBA1 and alpha-synuclein in Parkinson disease

    L. Smith, M. Gegg, D. Chau, AHV. Schapira (London, United Kingdom)

  • The role of intraoperative electrophysiological monitoring in implanting globus pallidus internus electrodes in patients with dystonia

    J. Kunst, D. Hrabovsky, T. Jurkova, J. Chrastina, M. Balaz (Brno, Czech Republic)

  • The role of Parkinson Nurses for personalizing care in Parkinson’s Disease: a systematic review and meta-analysis

    J. Stümpel, M. van Munster, T. Mestre, D. Pedrosa (Cologne, Germany)

  • The role of stimulation parameters on cognitive performance in Essential Tremor with DBS ViM

    J. Kane, J. Neimat, S. Wylie, F. Phibbs, P. Hedera, V. Holiday, N. van Wouwe (Louisville, USA)

  • The Rostock International Parkinson’s Disease (ROPAD) Study: Analysis of Monogenic PD Genes

    A. Westenberger, V. Skrahina, C. Beetz, T. Usnich, E-J. Vollstedt, X. Bogdanovic, N. Schell, M. Olmedillas, F. Curado, J. Paul, S. Skobalj, N. Brüggemann, N. Ameziane, I. Csoti, M. Kasten, C. Klein, P. Bauer, A. Rolfs (Lübeck, Germany)

  • The severity of tics in patients with Gilles de la Tourette syndrome and comorbid Autism Spectrum Disorder

    J. Kaczyńska, P. Janik (Warsaw, Poland)

  • The shaky truth of a Movement Disorder Nurse pilot program in Rural Australia

    L. Bellizzi (Horsham, Australia)

  • The Spectrum of Movement Disorders Associated With NUS1 Pathogenic Variants

    NE. Mencacci, N. Prakash, E. Gerard, L. Kinsley, BK. Bölsterli, R. Steinfeld, C. Ellis, T. Tropea, T. Bardakjian, A. Lavillaureix, M. Ugolin, C. Thauvin-Robinet, M. Brugger, KM. Riedhammer, T. Opladen, T. Wirth, C. Tranchant, M. Anheim, J. Chelly, BA. Mendelsohn, S. Nandipati, A. Stembridge, HS. Dafsari, H. Zempel, P. Herkenrath, S. Mercimek-Andrews, T. Laut, J. Necpal, R. Jech, M. Zech, G. Trieschmann, S. Berweck, O. Vanakker, D. Gill, F. Gardiner, S. Mohammad, H. Mefford, I. Scheffer, G. Carvill, D. Krainc (Chicago, USA)

  • The START Study: A Phase 4 Study on the Real-World Utilization of Deutetrabenazine Initiated by a 4-Week Patient Titration Kit

    K. Anderson, M. Konings, S. Finkbeiner, A. Cutler (Washington, USA)

  • The STEPWISE Parkinson study: a Smartphone Based Exercise Solution for Patients With Parkinson’s Disease

    S. Schootemeijer, N. de Vries, E. Macklin, A. Ascherio, M. Schwarzschild, B. Bloem (Nijmegen, Netherlands)

  • The study of clonidine growth hormone study amongst definite MSA, PD, PSP, and PAF patients to assess its feasibility as a future non-invasive biomarker

    S. Bhattacharjee, E. Vichayanrat, L. Watson, V. Iodice (London, United Kingdom)

  • The study of genetic factors in motor levodopa-induced complications development in Russian patients with Parkinson’s disease

    G. Akhmadeeva, I. Khidiyatova, I. Gilyazova, S. Umutbaev, A. Baitimerov, O. Kachemaeva, R. Galimova, R. Magzhanov (Ufa, Russian Federation)

  • The Unmet needs for advanced Parkinson Disease in -Patients’ during the Covid-19 pandemic in Israel

    N. Simantov, A. Socher, T. Gurevich (Tel-Aviv, Israel)

  • The use of artificial intelligence-based chatbot in Parkinson’s disease

    G. Oyama, M. Ogawa, K. Morito, M. Kobayashi, Y. Yamada, K. Shinkawa, H. Kamo, T. Hatano, N. Hattori (Tokyo, Japan)

  • The USP Project: Understanding the Scope and Value of Parkinson’s Specialist Nursing

    A. Hand, K. Mcewan, A. Clarke, S. Dalkin, A. Bate, R. Bradford, C. Allen, K. Mcdonald, S. Mccarthy, K. Brittain (Newcastle-upon-Tyne, United Kingdom)

  • The Vall d’Hebron Initiative for Parkinson (VHIP) cohort: a prospective, longitudinal and observational study enrolling de novo Parkinson’s disease (PD) patients and carriers of PD-linked mutations for biomarker and pathophysiology studies

    D. Samaniego-Toro, L. Domingo-Rodriguez, M. Camprodon-Gómez, M. Armengol-Bellapart, V. González, S. Lucas-Del-Pozo, E. Xicoy, J. Riera-Heredia, D. Montpeyó, M. Martinez-Vicente, A. Laguna, J. Hernandez-Vara (Barcelona, Spain)

  • Therapeutic approach to botulinum injections for hemifacial spasm, post facial paralysis synkinesis and blepharospasm

    G. Yahalom, A. Janah, R. Eichel (Jerusalem, Israel)

  • Therapeutic potential of luteolin in manganese induced Parkinson’s disease: Targeting neuroinflammation and oxidative stress.

    S. Chib (Moga, India)

  • Therapies, Research Funding and Racial Diversity in Cerebellar Ataxia: A Systematic Review of the Literature

    C. Kingsbury, S. Ghanekar, Y. Huang, T. Ashizawa, S. Kuo, C. Gooch, T. Zesiewicz (Tampa, USA)

  • Therapies, Research Funding and Racial Diversity in Essential Tremor: A Systematic Review of the Literature

    T. Zesiewicz, J. Vega, C. Gooch, S. Ghanekar, Y. Huang, Y. Bezchlibnyk, J. Staffettiij, C. Kingsbury (Tampa, USA)

  • Therapy resistant tremor in Parkinson’s disease. Satisfying an unmet need.

    SW. Pedersen, L. Johannsen (Frederiksberg, Denmark)

  • Theta-burst Cycling for Deep Brain Stimulation

    J. Maclean, J. Olaya, M. Liker, T. Sanger (Orange, USA)

  • Three patients with PSP presenting with a logopenic pattern of aphasia: expanding the phenotype of language impairment in PSP.

    S. Lyons, R. Walsh, T. Lynch, S. O'Dowd (Dublin, Ireland)

  • Throat Clearing tics In Wilson’s Disease- An Unusual Manifestation

    V H. Ganaraja, A. Konnur, S. Kodapala (BENGALURU, India)

  • Time reproduction in Parkinson’s disease: Is there a specific impairment in context of movements?

    M. Ruppert, L. Torfah, V. Hammes, A. Greuel, F. Maier, L. Timmermann, D. Pedrosa Carrasco, C. Eggers (Marburg, Germany)

  • Time-to-event approach mitigates the treatment masking effect of symptomatics on MDS-UPDRS Part III

    S. Zanigni, N. Shariati, T. Simuni, N. Pavese, K. Marek, R. Postuma, A. Monnet, E. Moore, A. Hahn, E. Davies, N. Pross, D. Trundell, T. Nikolcheva, G. Pagano (Basel, Switzerland)

  • Tissue Frataxin Increases After Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia

    D. Bettoun, T. Galas, D. Schecter, N. Ruiz, R. Clayton, J. Farmer (Bala Cynwyd, USA)

  • To be or not to bupropion: a drug-induced parkinsonism?

    A. Silva, J. Pinto, M. Gago, M. Rodrigues (Braga, Portugal)

  • To Prescribe or Not to Prescribe: Assessing the impact of Parkinson’s nurse prescribers

    A. Hand, K. Mcewan, A. Clarke, A. Bate, S. Dalkin, R. Bradford, C. Allen, K. Mcdonald, S. Mccarthy, K. Brittain (Newcastle upon Tyne, United Kingdom)

  • To scan or not to scan? Parkinsonian syndrome due to supratentorial glioblastoma

    P. Ferreira, R. Rocha, V. Carvalho (Matosinhos, Portugal)

  • Towards a Machine Learning Based Classification System for Hyperkinetic Movement Disorders: Generating a Neurophysiological Feature Set

    E. V.D. Brandhof, S. V.D. Veen, G. Russo, I. Tuitert, J. Dalenberg, M. V.D. Stouwe, J. Elting, M. Biehl, M. de Koning-Tijssen (Groningen, Netherlands)

  • Tracking longitudinal changes in MSA: TALISMAN study protocol

    W. Meissner, A. Varrone, A. Sahib, D. åström, J. Clarimon, A. Andreasen, A-K. Berger, J. Wiedemann, S. Sgarbi, D. Meulien (Pessac, France)

  • Transauricular Vagus Nerve Stimulation (taVNS) for mild to moderate Parkinson’s Disease (PD)

    V. Hinson, C. Mcleod, B. Badran, H. Boger, L. Lovera, A. Phan, J. Elm, T. Turner (Charleston, USA)

  • Transcranial alternating current stimulation modulates motor network connectivity in patients with blepharospasm

    K. Popli, H. Nawaz, M. Barrett, M. Palenzuela, D. Peterson, B. Berman (Richmond, USA)

  • Transcranial magnetic resonance-guided focused ultrasound in Lance-Adams syndrome

    R. Galimova, YU. Sidorova, G. Akhmadeeva, O. Kachemaeva, D. Krekotin, I. Buzaev, N. Muhamadeeva (Ufa, Russian Federation)

  • Transcranial static magnetic field stimulation of the primary motor cortex in essential tremor

    D. Urso, C. Ammann, M. Monje, B. Fernández-Rodríguez, L. Vela, A. Oliviero, J. Obeso, G. Foffani (Madrid, Spain)

  • Transcutaneous auricular vagal nerve stimulation has frequency depended propensity to improve gait in Parkinson’s disease – a pilot study

    V. van Midden, Z. Pirtošek, G. Brecl Jakob, M. Kojović (Ljubljana, Slovenia)

  • Transition from paediatric to adult care – A satisfaction survey of young people with complex motor disorders and implanted devices.

    S. Perides, L. Keenan, V. Stevenson, M. Kaminska (London, United Kingdom)

  • Treating Upper Limb Spasticity With OnabotulinumtoxinA: Subgroup Analysis of US Practice Patterns From the ASPIRE Study

    G. Francisco, W. Feng, M. Munin, K. Ngo, M. Schwartz, M. Sadeghi, A. Zuzek, A. Esquenazi (Houston, USA)

  • Treatment of upper limb dystonic tremors: a retrospective study

    B. Gonzalez-Herrero, I. Di Vico, M. Edwards, F. Morgante (London, United Kingdom)

  • Treatment Selection in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease: The Search for the Ideal Neuroprotective Drug

    C. Gonzalez-Robles, D. Byrom, R. Chapman, D. Dexter, S. Duty, R. Ellis-Doyle, E. Jabbari, G. Mills, H. Mortiboys, J. Rudiger, E. Sammler, P. Scurfield, S. Stott, G. Tofaris, L. Wei, A. Wong, ML. Zeissler, C. Carroll, T. Foltynie, O. Bandmann, A. Schapira (London, United Kingdom)

  • TREMOR AND BRADYKINESIA ARE TWO UNRELATED SIDE EFFECTS INDUCED BY VALPROATE INTAKE

    A. de Biase, G. Paparella, L. Angelini, A. Cannavacciuolo, D. Colella, E. Cerulli Irelli, A. Gialllonardo, C. Di Bonaventura, A. Berardelli, M. Bologna (Rome, Italy)

  • Tremor as a Hallmark of Neurodegeneration and Mercury Intoxication

    D. Labunskiy, S. Kiryukhina, N. Kolmykova, N. Kurgaev (Saransk, Russian Federation)

  • Tremor genetics in clinical practice: a systematic literature review

    C. Everlo, M. Tijssen, C. Marras, C. Klein, D. Verbeek, T. de Koning, M. V.D. Stouwe (Groningen, Netherlands)

  • Tremor in patients with myotonic dystrophy type 2

    N. Dragašević Mišković, A. Milovanovic, S. Perić, M. Badža, B. Bjelica, I. Vajs, V. Bobić, č. Jovanović, V. Rakočević, I. Basta, M. Svetel, M. đurić, V. Kostić (Belgrade)

  • Trending the educational needs of US physicians related to managing patients with tardive dyskinesia

    W. Cerenzia, S. Wiley, B. Coleman, S. Stacy, E. Jen, K. Farahmand, S. Siegert, C. Shah (Birmingham, USA)

  • Trends in incidence of hospitalizations in Parkinson´s Disease in Spain (2010-2019)

    V. Gómez-Mayordomo, R. Jiménez-García, E. Sanesteban-Beceiro, E. López-Valdés, R. García-Ramos, F. Alonso-Frech (Madrid, Spain)

  • TRPV4 Mutation related Parkinson’s Disease with Scapuloperoneal spinal muscular atrophy

    A. Deenadayalu, P. A, V. Paramanandam (Limerick, Ireland)

  • Tullio phenomenon in CANVAS Syndrome

    T. Liu, N. Badihian, L. Jackson, A. Hassan, E. Coon (Rochester, USA)

  • Turning during single and dual tasking in Parkinson’s Disease

    E. Bianchini, E. Warmerdam, R. Romijnders, J. Hoffmann, G. Schmidt, F. Pontieri, C. Hansen, W. Maetzler (Rome, Italy)

  • TWNK in Parkinson’s disease: a Movement Disorder and Mitochondrial Disease Center perspective study

    M. Percetti, G. Franco, E. Monfrini, L. Caporali, R. Minardi, C. La Morgia, M. Valentino, R. Liguori, I. Palmieri, D. Ottaviani, M. Vizziello, D. Ronchi, F. Di Berardino, A. Cocco, G. Comi, A. Albanese, B. Giometto, E. Valente, V. Carelli, A. Di Fonzo (Milano, Italy)

  • Two cases of myoclonic ataxia with and without epilepsy associated with NUS1

    G. Riboldi, E. Monfrini, C. Miller, A. Di Fonzo, S. Frucht (New York, USA)

  • Two cases of severe generalized dystonia in IRF2BPL and response to treatment

    M. Hull, M. Parnes (Houston, USA)

  • Two Different Clinical Presentations in SYNE1 Ataxia in Turkey

    Y. Secil, A. Subasioglu (İzmir, Turkey)

  • TWO-DIMENSIONAL SMOOTH PURSUIT TESTS FOR EARLY PARKINSON’S DISEASE IDENTIFICATION

    E. Luque-Buzo, A. Burlaka-Petrash, J. Gómez-García, M. Bejani, M. Del Valle-Loarte, F. Grandas, J. Godino-Llorente (Madrid, Spain)

  • TWO-YEAR LONGITUDINAL FOLLOW-UP OF VISUAL ILLUSIONS AND HALLUCINATIONS IN PARKINSON’S DISEASE

    S. Beze, L. Castellani, B. Pereira, F. Chiambaretta, F. Durif, A. Marques (Clermont-Ferrand, France)

  • Type 2 diabetes-associated transcriptomic changes in Parkinson’s disease and non-neurodegenerative control brains.

    P. Cullinane, E. de Pablo-Fernandez, K. Ebanks, Z. Jaunmuktane, T. Warner (London, United Kingdom)

Jump to:  View All • a b c d e f g h i j k l m n o p q r s [t] u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
        • Help & Support
        • About Us
        • Cookies & Privacy
        • Wiley Job Network
        • Terms & Conditions
        • Advertisers & Agents
        Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
        Wiley